Reading AIM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIM free→
AIM IMMUNOTECH INC (AIM)
AMEXHealth CareBiotechnologySnapshot 2026-06-16
Watch· this week
$0.39+1.31%
Close 2026-06-16 · 1-day change
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is neutral. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been unsteady, with frequent changes. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, AIM is below typical. Peer multiples imply a price about 11% above where it trades (it looks cheap on this basis); the read is fair, but weakening. This assessment is provisional.
as of 2026-06-16
Quick facts
- Exchange
- AMEX
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $10.46M
- Employees
- —
- IPO date
- 1996-05-14
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.39. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$1.40consensus
Range $1.40 – $1.40
vs price: -72% below
Method agreement — · 1 method
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$2.11consensus
Range $1.52 – $2.70
vs price: -81% below
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Re-ratingmedium confidence
At $0.39 AIM trades at 16× p/s — 1.7× the 10× p/s peer median. The market is re-rating it beyond its own range; our $0.44 fair value is medium-confidence here. Not investment advice.
Multiple (P/S)
16.4x
peer 9.6x · own history —
Premium
1.7x peer
Growth the price needs
-11%
our forecast -21%
Our fair value
$0.44
range $0.34 – $0.55
WhyEarnings too small for P/E
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensivefair — but weakening12-month view
What's priced inStretched
The price implies about 11% below a flat-multiple fair value, ahead of our forecast of about -21%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Historical context
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
41st pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.85x of net income into operating cash flow.
Macro sensitivity
Not enough signal yet.
Management & capital allocation
volatile23 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
3rd pctl · Health Care
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
BullishEPS revised +67.6% / 30d, n=1for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.37 → $-0.12 (+67.6% / 30d). 1 raised, 0 cut, 1 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
Material events
1 positive, 4 negative / 30d. See F4 management tile for the event list.
Transition story with positive analyst positioning (often a turnaround setup).
Sector context
Intermediate · Weeklyheadwind
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weak
- Capital allocation
- weak
- Earnings discipline
- weak
- Margin discipline
- weak
- Balance sheet
- weak
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
Not enough price history for this read.
How much price usually moves either way.
Not enough price history for this read.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,609.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
As of June 16, 2026, the valuation dimension changed and rose. The valuation label changed from "inexpensive" to "fair." This indicates a shift in how the stock is perceived in terms of its price relative to its value. The overall context remains provisional, with other dimensions such as earnings quality and risk still indicating challenges.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-05-2027d agoMarkets Insider
Advances: Debt issuance for capital raising
Financing supports capital raising objective.
ReinforcesConfirmed
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting AIM and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for AIM and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping AIM and other Healthcare names could fade. Watch these names for early warning.
- If AIM misses again next quarter like this past one (a big miss of -86% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits AIM and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-116d agoItem 1.01
Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189…
Capital allocationneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+1.0 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.